Our group reported a few months ago the first case of a patient who was treated by trastuzumab and lapatinib as third line regimen for ERBB2-negative metastatic breast cancer on the basis of an activating ERBB3 mutation retrieved by all-exome sequencing in both the primary tumor and liver metastases [19]. This evidence concerns the gene ERBB3 and neoplasm.